<DOC>
	<DOCNO>NCT02820961</DOCNO>
	<brief_summary>The purpose study determine effect exemestane pharmacokinetics ( PK ) entinostat determine effect entinostat PK exemestane patient locally recurrent metastatic estrogen receptor positive ( ER+ ) breast cancer . Additionally , study evaluate safety tolerability entinostat combination exemestane , assess effectiveness entinostat combination exemestane term best overall response overall survival .</brief_summary>
	<brief_title>Drug-Drug Interaction Study Entinostat Exemestane Postmenopausal Women With ER+ Breast Cancer</brief_title>
	<detailed_description>SNDX-275-0130 Phase 1 , two-cohort , open-label , drug-drug interaction study entinostat exemestane . All patient enrol one two cohort receive either entinostat monotherapy follow entinostat plus exemestane ( Cohort 1 ) , exemestane monotherapy follow exemestane plus entinostat ( Cohort 2 ) . The cohort enroll sequentially , mean Cohort 1 enroll prior Cohort 2 . Cohort 1 evaluate exemestane 's effect PK entinostat . Cohort 2 evaluate entinostat 's effect PK exemestane . In Cohorts , treatment cycle 28 day . Patients participate one cohort . All patient assess Screening specify time conduct study use standard clinical laboratory assessment . Patients also assess tumor response per standard care Screening Period . Response treatment assess computerized tomography ( CT ) , magnetic resonance imaging ( MRI ) bone scan appropriate . Patients continue receive appropriate cycle study treatment tumor progression adverse event ( AEs ) occur necessitate discontinuing therapy determine Investigator .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Entinostat</mesh_term>
	<criteria>Postmenopausal female patient Histologically cytologically confirm ER+ breast cancer initial diagnosis locally recurrent metastatic disease progress patient candidate receive exemestane determine Investigator Patients receive palliative radiation nontarget lesion must clinically stable prior receive first dose study treatment Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Patient must acceptable , applicable laboratory requirement Patients may history brain metastasis provide certain protocol criterion meet Able understand give write informed consent comply study procedure Rapidly progressive lifethreatening metastasis Inability swallow oral medication gastrointestinal ( GI ) malabsorption syndromes History significant GI surgery determine Investigator A medical condition precludes adequate study treatment increase patient risk Currently enrol ( complete within 30 day prior study drug administration ) another investigational drug study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Breast Neoplasms</keyword>
	<keyword>Breast Diseases</keyword>
	<keyword>Exemestane</keyword>
	<keyword>Protein Kinase Inhibitors</keyword>
	<keyword>Aromatase Inhibitors</keyword>
	<keyword>entinostat</keyword>
	<keyword>Cancer Breast</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Hormone Receptor Positive Breast Cancer</keyword>
	<keyword>Estrogen Receptor</keyword>
	<keyword>ER+ Breast Cancer</keyword>
	<keyword>Breast Tumor</keyword>
</DOC>